Head of group
Academic and research staff
- Dr Laura Broughton - Research Development Assistant in Academic Oncology, Castle Hill Hospital
- Dr Kathryn Date - Clinical Research Development Assistant (currently on maternity)
- Dr Antony Maraveyas - Reader in Oncology
Professional services staff
Postgraduate students
- Zainab Al-Ali - PhD student
- Tahani Al-Resheedi - PhD student
- Fada Jabber - PhD student
- Gillian Jackson - PhD student
- Boon-Uma Jowanaridhi - PhD student
- Rhiannon Lee - PhD student
- Sharjeela Tariq - MD student
Preclinical Positron Emission Tomography (PET) research project
The aim of this project is to produce radioisotopes using a cyclotron which can be incorporated into targeting molecules and, using a PET/CT scanner, be used for early diagnosis of diseases such as cancer and dementia.
Funded by: The Daisy Appeal, Dr Assem Allam and the University of Hull
Yorkshire Cancer Research Centre for early phase clinical trials
This project proposes the development of a Yorkshire-centred early clinical trials network, addressing scientifically-driven research questions of relevance to the Yorkshire population. Funding is requested to support the necessary infrastructure across the county, led by a steering group of experienced researchers from each centre. The focus is on proof of concept and feasibility studies covering specific research areas of strength including radiotherapy/drug combinations, biological therapies and novel therapeutic targets in order to accelerate through-flow of new cancer treatments from bench to bedside. The project will also provide support and mentorship to early-career clinicians to develop the clinical research leaders of the future.
Funded by: Yorkshire Cancer Research
Peripheral blood detection of EGFR status in lung cancer patients
Lung cancer is the single biggest killer from malignant disease in Yorkshire, with nearly 6000 new cases diagnosed each year. Approximately 10 per cent of patients have a mutation in a protein on the surface of their lung cancer cells called the epidermal growth factor receptor (EGFR). Knowledge of this mutation in individual patients is important as these patients respond to a class of drugs called receptor tyrosine kinase inhibitors rather than conventional chemotherapy with fewer side effects. However, to ascertain whether a patient has a mutation, a biopsy is required. Biopsies of lung tumours may be hazardous and can cause haemorrhage or lung collapse, and only 70 per cent of patients with lung cancer get a biopsy for these reasons. This study has developed a method of obtaining EGFR status from a peripheral blood sample which should make the treatment available to more lung cancer patients.
Funded by: Yorkshire Cancer Research
Reducing inequalities in cancer outcomes in Yorkshire: Realising our potential for innovation in diagnosis, patient management, survivorship and palliative care research
The death rate from cancer is higher in Yorkshire than the rest of England, resulting in about 200 extra deaths each year, of which more than half are in Hull. There are other significant cancer outcome inequalities between different groups; for example poorer people and older people are more likely to die sooner. This project aims to conduct research to understand these differences, and develop and test ways to reduce the inequalities and improve access to care and best treatments.
Funded by: Yorkshire Cancer Research
Urinary Tissue Factor Signal Transduction Peptides (uTF-STP) as a diagnostic marker for urothelial carcinoma of the bladder
Funded by: C-term Diagnostics Limited
MicroRNA-31 regulates chemosensitivity in malignant pleural mesothelioma
Funded by: Kazan McClain Partners Foundation